Business · 30/12/2002Updated: 10/17/2026 · 1 min read
FDA Clears Path for Diazepam Autoinjector Approval
Summary
The Food and Drug Administration (FDA) has determined that the Diazepam Autoinjector, a 5mg/mL formulation of diazepam for injection, was not withdrawn from sale due to safety or effectiveness concerns. This decision enables the FDA to approve abbreviated new drug applications (ANDAs) for this product.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →